pangi-shutterstock-com

PANGI / Shutterstock.com

6 June 2016Americas

Biosimilars and biologics: the life sciences battleground

“We’re looking back on a sustained attack on patents generally for the past decade,” explains Hans Sauer, deputy general counsel for intellectual property at the Biotechnology Innovation Organization (BIO).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

‘A marathon and a sprint at the same time’: How we won $452m damages

Judge denies Intellia bid to throw out suit over $100m Regeneron pact